Patents by Inventor Peter H. Seeberger

Peter H. Seeberger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10864261
    Abstract: The present invention relates to a synthetic saccharide of general formula (I) that is related to Streptococcus pneumoniae serotype 2 capsular polysaccharide, a conjugate thereof and the use of said saccharide and conjugate for raising a protective immune response in a human and/or animal host. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae type 2 bacteria.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: December 15, 2020
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Peter H. Seeberger, Claney Lebev Pereira, Chakkumkal Anish, Naeem Khan, Madhu Emmadi
  • Patent number: 10688169
    Abstract: The present invention relates to synthetic saccharides of general formula (I): V*—[Ux+2—Ux+1—Ux]n—V—O-L-NH2 that are related to carbapenem-resistant Klebsiella pneumoniae capsular polysaccharide and conjugates thereof. Said conjugates and pharmaceutical composition containing said conjugates are useful for prevention and/or treatment of diseases associated with carbapenem-resistant Klebsiella pneumoniae. Furthermore, the synthetic saccharides of general formula (I): V*—[Ux+2—Ux+1—Ux]n—V—O-L-NH2 are useful as marker in immunological assays for detection of antibodies against carbapenem-resistant Klebsiella pneumoniae bacteria.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: June 23, 2020
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Peter H. Seeberger, Claney Lebev Pereira, Guozhi Xiao, Naeem Khan, Chakkumkal Anish
  • Patent number: 10596272
    Abstract: The present invention relates to well-defined synthetic saccharides of general formula (I) that are related to the repeating unit of Streptococcus pneumoniae serotype 5 capsular polysaccharide and conjugates thereof. The conjugates and pharmaceutical compositions containing said conjugates are useful for prevention and/or treatment of diseases associated with Streptococcus pneumoniae, and more specifically against diseases associated with Streptococcus pneumoniae serotype 5. Furthermore, the synthetic saccharides of general formula (I) are useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae bacteria.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: March 24, 2020
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Chakkumkal Anish, Marilda Lisboa, Christopher Martin, Claney Lebev Pereira, Peter H. Seeberger, Naeem Khan
  • Patent number: 10588962
    Abstract: The present invention relates to the field of synthesizing and biologically evaluating of a novel class of carbohydrate-based vaccines. The new vaccines consist of a multi-modular structure which allows applying the vaccine to a whole variety of pathogenes. This method allows preparing vaccines against all pathogens expressing immunogenic carbohydrate antigens. As conjugation of antigenic carbohydrates to proteins is not required the conjugate vaccine is particularly heat stable. No refrigeration is required, a major drawback of protein-based vaccines.
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: March 17, 2020
    Assignees: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., UNIVERSITÄTSSPITAL BASEL
    Inventors: Peter H. Seeberger, Pierre Stallforth, Gennaro De Libero, Marco Cavallari
  • Publication number: 20200016257
    Abstract: The present invention relates to a synthetic saccharide of general formula (I) that is related to Streptococcus pneumoniae serotype 2 capsular polysaccharide, a conjugate thereof and the use of said saccharide and conjugate for raising a protective immune response in a human and/or animal host. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae type 2 bacteria.
    Type: Application
    Filed: December 16, 2016
    Publication date: January 16, 2020
    Inventors: Peter H. Seeberger, Claney Lebev Pereira, Chakkumkal Anish, Naeem Khan, Madhu Emmadi
  • Publication number: 20190240309
    Abstract: The present invention relates to immunogenic compositions comprising a conjugate of a saccharide from Streptococcus pneumoniae serotype 8 and a carrier protein, and a mixture consisting of capsular polysaccharides from Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F individually conjugated to CRM197 carrier protein, or a mixture consisting of capsular polysaccharides from Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F individually conjugated to a carrier protein, wherein the capsular polysaccharides from Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, and 23F are individually conjugated to protein D, the capsular polysaccharide from Streptococcus pneumoniae serotype 18C is conjugated to tetanus toxoid and the capsular polysaccharide from Streptococcus pneumoniae serotype 19F is conjugated to diphtheria toxoid. Said compositions are useful for the prevention and/or treatment of diseases caused by Streptococcus pneumoniae.
    Type: Application
    Filed: June 22, 2017
    Publication date: August 8, 2019
    Inventors: Peter H. Seeberger, Claney Lebev Pereira, Madhu Emmadi, Sharavathi Guddehalli Parameswarappa, Adam Calow, Petra Menova, Marilda Lisboa, Christopher Martin, Benjamin Schumann, Fei-Fei Xu, Naeem Khan, Paulina Kaplonek, Lennart Lykke
  • Patent number: 10328141
    Abstract: The present invention relates to the total synthesis of saccharide structures contained in the capsular polysaccharide of Streptococcus pneumoniae type 1, to glycoconjugates containing said saccharide structures obtained by total synthesis and to use of such glycoconjugates and pharmaceutical compositions thereof in the immunization against diseases associated with bacteria containing said saccharide structures in their capsular polysaccharide, and more specifically associated with Streptococcus pneumoniae.
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: June 25, 2019
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V.
    Inventors: Peter H. Seeberger, Claney Lebev Pereira, Chakkumkal Anish, Benjamin Schumann
  • Publication number: 20190153015
    Abstract: The present invention provides a stable synthetic saccharide of Hib polyribosylribitol-phosphate (PRP) derivative and conjugate thereof. Said saccharide, said conjugate and pharmaceutical compositions thereof are hydrolysis-resistant, long-term stable and useful for the prevention and/or treatment of diseases associated with Haemophilus influenzae, and more specifically of diseases associated with Haemophilus influenzae type b, preferably diseases selected from meningitis, pneumonia, and epiglotitis. They have general formula (I): wherein A is formula (II) or formula (III); B is formula (IV); C is formula (V); D is formula (VI); E is formula (VII); F is formula (VIII) or formula (IX).
    Type: Application
    Filed: July 28, 2017
    Publication date: May 23, 2019
    Inventors: Peter H. Seeberger, Claney Lebev Pereira
  • Publication number: 20190119313
    Abstract: The present invention relates to the preparation of a synthetic tetrasaccharide, hexasaccharide and octasaccharide representing part of the repeating unit of the Streptococcus pneumoniae type 3 capsular polysaccharide as well as conjugates thereof. Said conjugates are particularly useful for prevention and/or treatment of diseases associated with Streptococcus pneumoniae, and more specifically of diseases associated with Streptococcus pneumoniae type 3. The disclosed synthetic method has the huge advantages over the state of the art synthetic methods that intermediate products are crystalline, coupling reaction yields are higher, less reaction steps are required and purification of intermediate products is easier.
    Type: Application
    Filed: April 18, 2017
    Publication date: April 25, 2019
    Inventors: Peter H. Seeberger, Claney Lebev Pereira, Sharavathi Guddehalli Parameswarappa, Adam Daniel James Calow, Petra Menova, Ju Yuel Baek
  • Patent number: 10220083
    Abstract: The present invention relates to synthetic saccharides of general formula (I) that are related to Streptococcus pneumoniae serotype 8 capsular polysaccharide, conjugates thereof and the use of said saccharides and conjugates for raising a protective immune response in a human and/or animal host. Furthermore, the synthetic saccharide structures of general formula (I) are useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae bacteria.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: March 5, 2019
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Peter H. Seeberger, Claney Lebev Pereira, Chakkumkal Anish, Benjamin Schumann, Sharavathi Guddehalli Parameswarappa, Heung Sik Hahm, Subramanian Govindan
  • Patent number: 10188718
    Abstract: The present invention relates to synthetic saccharides of general formula (I) that are related to Streptococcus pneumoniae serotype 4 capsular polysaccharide and conjugates thereof. Said conjugate and a pharmaceutical composition containing said conjugate are useful for prevention and/or treatment of diseases associated with Streptococcus pneumoniae, and more specifically of diseases associated with Streptococcus pneumoniae serotype 4. Furthermore, the synthetic saccharides of general formula (I) are useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae bacteria.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: January 29, 2019
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Peter H. Seeberger, Claney Lebev Pereira, Chakkumkal Anish, Andreas Geissner
  • Publication number: 20180296687
    Abstract: The present invention relates to well-defined synthetic saccharides of general formula (I) that are related to the repeating unit of Streptococcus pneumoniae serotype 5 capsular polysaccharide and conjugates thereof. The conjugates and pharmaceutical compositions containing said conjugates are useful for prevention and/or treatment of diseases associated with Streptococcus pneumoniae, and more specifically against diseases associated with Streptococcus pneumoniae serotype 5. Furthermore, the synthetic saccharides of general formula (I) are useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae bacteria.
    Type: Application
    Filed: January 26, 2016
    Publication date: October 18, 2018
    Inventors: Chakkumkal ANISH, Marilda LISBOA, Christopher MARTIN, Claney Lebev PEREIRA, Peter H. SEEBERGER, Naeem KHAN
  • Patent number: 10052373
    Abstract: The present invention provides a protein- and peptide-free conjugate comprising a synthetic carbohydrate and a carrier molecule, wherein the synthetic carbohydrate is a Streptococcus pneumoniae type 3 capsular polysaccharide related carbohydrate and the carrier molecule is a glycosphingolipid. Said conjugate and pharmaceutical composition thereof are useful for immunization against diseases associated with Streptococcus pneumoniae, and more specifically against diseases associated with Streptococcus pneumoniae type 3.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: August 21, 2018
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Dominea Rathwell, Sharavathi Guddehalli Parameswarappa, Subramanian Govindan, Chakkumkal Anish, Claney Lebev Pereira, Peter H. Seeberger, Felix Bröcker
  • Publication number: 20180078630
    Abstract: The present invention relates to synthetic saccharides of general formula (I): V*—[Ux+2—Ux+1—Ux]n—V—O-L-NH2 that are related to carbapenem-resistant Klebsiella pneumoniae capsular polysaccharide and conjugates thereof. Said conjugates and pharmaceutical composition containing said conjugates are useful for prevention and/or treatment of diseases associated with carbapenem-resistant Klebsiella pneumoniae. Furthermore, the synthetic saccharides of general formula (I): V*—[Ux+2—Ux+1—Ux]n—V—O-L-NH2 are useful as marker in immunological assays for detection of antibodies against carbapenem-resistant Klebsiella pneumoniae bacteria.
    Type: Application
    Filed: March 29, 2016
    Publication date: March 22, 2018
    Inventors: Peter H. Seeberger, Claney Lebev Pereira, Guozhi Xiao, Naeem Khan, Chakkumkal Anish
  • Publication number: 20170333545
    Abstract: The present invention relates to synthetic saccharides of general formula (I) that are related to Streptococcus pneumoniae serotype 4 capsular polysaccharide and conjugates thereof. Said conjugate and a pharmaceutical composition containing said conjugate are useful for prevention and/or treatment of diseases associated with Streptococcus pneumoniae, and more specifically of diseases associated with Streptococcus pneumoniae serotype 4. Furthermore, the synthetic saccharides of general formula (I) are useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae bacteria.
    Type: Application
    Filed: May 15, 2015
    Publication date: November 23, 2017
    Inventors: Peter H. Seeberger, Claney Lebev Pereira, Chakkumkal Anish, Andreas Geissner
  • Patent number: 9815889
    Abstract: The present invention relates to an antibody having specificity for an immunogenic determinant consisting of the pentasaccharide repeating unit of the Clostridium difficile glycopolymer PS-I: ?-L-Rhap-(1?3)-?-D-Glcp-(1?4)-[?-L-Rhap-(1?3)]-?-D-Glcp-(1?2)-?-D-Glcp or a fragment thereof. Said antibody is able to prevent and treat diseases caused by C. difficile. The present invention further pertains to a method of treating or preventing a disease caused by the pathogen Clostridium difficile, which comprises administering to a subject said antibody or a vaccine composition comprising said antibody.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: November 14, 2017
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Peter H. Seeberger, Christopher E. Martin, Felix Broecker, Chakkumkal Anish
  • Patent number: 9802974
    Abstract: The present invention relates to the synthesis of GPI-related surface antigens of the parasite Toxoplasma gondii (T. gondii) and the resulting products obtained. These synthetic compounds are suitable for diagnosis of toxoplasmosis, as well as vaccine against toxoplasmosis, a diseases caused by infection with T. gondii.
    Type: Grant
    Filed: July 23, 2013
    Date of Patent: October 31, 2017
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Nahid Azzouz, Sebastian Götze, Peter H. Seeberger, Daniel Varon Silva, Yu-Hsuan Tsai
  • Patent number: 9802952
    Abstract: The present invention is directed to a method for continuous production of dihydroartemisinin and also artemisinin derivatives derived from dihydroartemisinin by using artemisinin or dihydroartemisinic acid (DHAA) as starting material as well as to a continuous flow reactor for producing dihydroartemisinin as well as the artemisinin derivatives. It was found that the reduction of artemisinin to dihydroartemisinin in a continuous process requires a special kind of reactor and a special combination of reagents comprising a hydride reducing agent, at least one activator such as an inorganic activator, at least one solid base, at least one aprotic solvent and at least one C1-C5 alcohol.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: October 31, 2017
    Assignee: Max-Plank-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Daniel Kopetzki, David Tyler McQuade, Peter H. Seeberger, Kerry Gilmore
  • Publication number: 20170239341
    Abstract: The present invention relates to synthetic saccharides of general formula (I) that are related to Streptococcus pneumoniae serotype 8 capsular polysaccharide, conjugates thereof and the use of said saccharides and conjugates for raising a protective immune response in a human and/or animal host. Furthermore, the synthetic saccharide structures of general formula (I) are useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae bacteria.
    Type: Application
    Filed: September 28, 2015
    Publication date: August 24, 2017
    Inventors: Peter H. Seeberger, Claney Lebev Pereira, Chakkumkal Anish, Benjamin Schumann, Sharavathi Guddehalli Parameswarappa, Heung Sik Hahm, Subramanian Govindan
  • Patent number: 9676735
    Abstract: The invention relates to a process for the preparation of Efavirenz via an efficient transition metal catalyzed cyclization, to a device suitable to perform such process as well as to novel intermediates.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: June 13, 2017
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Camille A. Correia, Kerry Gilmore, David Tyler McQuade, Peter H. Seeberger